These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12753573)

  • 1. Effective open-label treatment of premenstrual dysphoric disorder with venlafaxine.
    Hsiao MC; Liu CY
    Psychiatry Clin Neurosci; 2003 Jun; 57(3):317-21. PubMed ID: 12753573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder.
    Cohen LS; Soares CN; Lyster A; Cassano P; Brandes M; Leblanc GA
    J Clin Psychopharmacol; 2004 Oct; 24(5):540-3. PubMed ID: 15349012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venlafaxine in the treatment of premenstrual dysphoric disorder.
    Freeman EW; Rickels K; Yonkers KA; Kunz NR; McPherson M; Upton GV
    Obstet Gynecol; 2001 Nov; 98(5 Pt 1):737-44. PubMed ID: 11704162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duloxetine for premenstrual dysphoric disorder: a pilot study.
    Mazza M; Harnic D; Catalano V; Janiri L; Bria P
    Expert Opin Pharmacother; 2008 Mar; 9(4):517-21. PubMed ID: 18312154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind, placebo-controlled pilot study of adjunctive quetiapine SR in the treatment of PMS/PMDD.
    Jackson C; Pearson B; Girdler S; Johnson J; Hamer RM; Killenberg S; Meltzer-Brody S
    Hum Psychopharmacol; 2015 Nov; 30(6):425-34. PubMed ID: 26193781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
    Lenox-Smith AJ; Jiang Q
    Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venlafaxine extended-release: a review of its use in the management of major depression.
    Wellington K; Perry CM
    CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venlafaxine extended-release for depression following spinal cord injury: a randomized clinical trial.
    Fann JR; Bombardier CH; Richards JS; Wilson CS; Heinemann AW; Warren AM; Brooks L; McCullumsmith CB; Temkin NR; Warms C; Tate DG;
    JAMA Psychiatry; 2015 Mar; 72(3):247-58. PubMed ID: 25607727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two items on the Hamilton Depression rating scale are effective predictors of remission: comparison of selective serotonin reuptake inhibitors with the combined serotonin/norepinephrine reuptake inhibitor, venlafaxine.
    Silverstone PH; Entsuah R; Hackett D
    Int Clin Psychopharmacol; 2002 Nov; 17(6):273-80. PubMed ID: 12409680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder.
    Rickels K; Mangano R; Khan A
    J Clin Psychopharmacol; 2004 Oct; 24(5):488-96. PubMed ID: 15349004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study.
    McIntyre A; Gendron A; McIntyre A
    Depress Anxiety; 2007; 24(7):487-94. PubMed ID: 17177199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group.
    Mehtonen OP; Søgaard J; Roponen P; Behnke K
    J Clin Psychiatry; 2000 Feb; 61(2):95-100. PubMed ID: 10732656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Response and remission in depressive patients with anxiety symptoms treated with venlafaxine extended release in primary care].
    Roca Benassar M; Baca Baldomero E
    Actas Esp Psiquiatr; 2006; 34(3):162-8. PubMed ID: 16736389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial.
    Yonkers KA; Kornstein SG; Gueorguieva R; Merry B; Van Steenburgh K; Altemus M
    JAMA Psychiatry; 2015 Oct; 72(10):1037-44. PubMed ID: 26351969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder.
    Silverstone PH; Salinas E
    J Clin Psychiatry; 2001 Jul; 62(7):523-9. PubMed ID: 11488362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group.
    Khan A; Upton GV; Rudolph RL; Entsuah R; Leventer SM
    J Clin Psychopharmacol; 1998 Feb; 18(1):19-25. PubMed ID: 9472838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Six-month paroxetine treatment of premenstrual dysphoric disorder: continuous versus intermittent treatment protocols.
    Wu KY; Liu CY; Hsiao MC
    Psychiatry Clin Neurosci; 2008 Feb; 62(1):109-14. PubMed ID: 18289149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of venlafaxine in psychiatric disorders and climacteric syndrome: is a therapeutic bridge?
    Luisi S; Castrogiovanni A; Ciani V; Pacchierotti C; Capua AD; Pasquini R; Lazzeri L; Petraglia F
    Gynecol Endocrinol; 2012 Jan; 28(1):68-71. PubMed ID: 22087587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venlafaxine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder.
    Findling RL; Greenhill LL; McNamara NK; Demeter CA; Kotler LA; O'Riordan MA; Myers C; Reed MD
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):433-45. PubMed ID: 17822339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo.
    Pearlstein TB; Halbreich U; Batzar ED; Brown CS; Endicott J; Frank E; Freeman EW; Harrison WM; Haskett RF; Stout AL; Yonkers KA
    J Clin Psychiatry; 2000 Feb; 61(2):101-9. PubMed ID: 10732657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.